医学
经皮冠状动脉介入治疗
内科学
心肌梗塞
心脏病学
队列
回顾性队列研究
前瞻性队列研究
弗雷明翰风险评分
推导
人口
外科
动脉
疾病
环境卫生
作者
Giovanni Luigi De Maria,Gregor Fahrni,Mohammad Alkhalil,Florim Cuculi,Sam Dawkins,Mathias Wolfrum,Robin P. Choudhury,J C Forfar,B D Prendergast,Tuncay Yetgin,Robert Jan van Geuns,Matteo Tebaldi,Keith M. Channon,Rajesh K. Kharbanda,P M Rothwell,Marco Valgimigli,Adrian P. Banning
出处
期刊:Eurointervention
[Europa Digital and Publishing]
日期:2016-11-01
卷期号:12 (10): 1223-1230
被引量:27
标识
DOI:10.4244/eijv12i10a202
摘要
Restoration of effective myocardial reperfusion by primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction is difficult to predict. A method to assess the likelihood of a suboptimal response to conventional pharmacomechanical therapies could be beneficial. We aimed to derive and validate a scoring system that can be used acutely at the time of coronary reopening to predict the likelihood of downstream microvascular impairment in patients with STEMI.A score estimating the risk of post-procedural microvascular injury defined by an index of microcirculatory resistance (IMR) >40 was initially derived in a cohort of 85 STEMI patients (derivation cohort). This score was then tested and validated in three further cohorts of patients (retrospective [30 patients], prospective [42 patients] and external [29 patients]). The ATI score (age [>50=1]; pre-stenting IMR [>40 and <100=1; ≥100=2]; thrombus score [4=1; 5=3]) was highly predictive of a post-stenting IMR >40 in all four cohorts (AUC: 0.87; p<0.001-derivation cohort, 0.84; p=0.002-retrospective cohort, 0.92; p<0.001-prospective cohort and 0.81; p=0.006-external cohort). In the whole population, an ATI score ≥4 presented a 95.1% risk of final IMR >40, while no cases of final IMR >40 occurred in the presence of an ATI score <2.The ATI score appears to be a promising tool capable of identifying patients during PPCI who are at the highest risk of coronary microvascular impairment following revascularisation. This procedural risk stratification has a number of potential research and clinical applications and warrants further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI